The development of highly-purified malaria vaccines remains a challenge. Using the Pfenex Psuedomonas fluorescens expression system, a recombinant vaccine was produced to support Phase I clinical trials. So what is the best way to control process-related impurities?Session: Control of Process-Related Impurities for a Recombinant Seasonal Influenza Vaccine
Speaker: Penny L. Post, PHh.D., Vice President, Regulatory, Protein Sciences Corporation
Join us for IBC's Inaugural Product and Process Variants & Impurities where we'll feature Flublok from Protein Sciences Corp., the first licensed egg-free recombinant influenza vaccine for adults, 18-49. In this presentation, Dr. Post shares the Meriden, CT-based company’s strategy for controlling process-related impurities and maintaining product quality. Want to learn more? Download our agenda.
As a reader of this blog, you'll receive 15% off of the standard rate when you mention code XB13194BLOG to register. We looking forward to seeing you October 21-23, in Washington, D.C.!
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment